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ABSTRACT
The effect of cis-diaminedichloroplatinum(II) (cis-
platin) DNA damage on the repair of double-strand
breaks by non-homologous end-joining (NHEJ) was
determined using cell-free extracts. NHEJ was dra-
maticallydecreasedwhenplasmidDNAwasdamaged
to contain multiple types of DNA adducts, along the
molecule and at the termini, by incubation of DNA
with cisplatin; this was a cisplatin concentration-
dependent effect. We investigated the effect a single
GTG cisplatination site starting 10 bp from the DNA
termini would have when surrounded by the regions
ofAT-richDNAwhichweredevoidofthemajoradduct
target sequences. Cisplatination of a substrate con-
taining short terminal 13–15 bp AT-rich sequences
reduced NHEJ to a greater extent than that of a sub-
strate with longer (31–33 bp) AT-rich sequences.
However, cisplatination at the single GTG site within
the AT sequence had no significant effect on NHEJ,
owing to the influence of additional minor monoad-
duct and dinucleotide adduct sites within the AT-rich
region and owing to the influence of cisplatination at
sitesupstreamoftheAT-richregions.Wethenstudied
the effect on NHEJ of one cis-[Pt(NH3)2{d(GpTpG)-
N7(1),-N7(3)} [abbreviated as 1,3-d(GpTpG)] cisplatin
adduct in the entire DNA molecule, which is more
reflective of the situation in vivo during concurr-
ent chemoradiation. The presence of a single 1,3-
d(GpTpG) cisplatin adduct 10 bases from each of
the two DNA ends to be joined resulted in a small
(30%) but significant decrease in NHEJ efficiency.
This process, which was DNA-dependent protein
kinase and Ku dependent, may in part explain the
radiosensitizing effect of cisplatin administered
during concurrent chemoradiation.
INTRODUCTION
Concurrent chemoradiation, the use of chemotherapy during
a course of radiotherapy, is now the standard treatment in
several cancer types and the subject of clinical trials in
others. However, the molecular mechanisms that make this
an effective treatment are not fully understood. cis-Diaminedi-
chloroplatinum(II) (cisplatin), an agent commonly used in
chemoradiation, acts by producing DNA interstrand and
intrastrand adducts. In vitro,  65% of the adducts are cis-
[Pt(NH3)2fd(GpG)-N7(1),-N7(2)g] [abbreviated as 1,2-d(GpG)]
intrastrand cross-links, 25% cis-[Pt(NH3)2fd(ApG)-N7(1),
-N7(2)g] [abbreviated as 1,2-d(ApG)] intrastrand cross-links,
5–10%1,3-d(GpNpG)intrastrandcross-links,withasmallper-
centage of interstrand cross-links and monofunctional adducts
[reviewed in (1)]. The intrastrand adducts are removed by nuc-
leotide excision repair (NER), which involves excision of a
regionof 30ntaroundtheadduct,followedbyDNAsynthesis
andligation(2).Radiationexposurecanproducemanytypesof
DNA damage including base damage,single-strand breaks and
double-strand breaks (DSBs). In a locally multiply damaged
site where a cisplatin adduct occurs close to a single-strand
break the damage may be initially repaired by NER. However,
duringthedualincisionstepaDSB,whichisthemostlethaltype
of damage a cell can sustain, could be produced (3). Alter-
natively, if a cisplatin adduct is close to a DSB, the DSB
could physically block the cisplatin removal and repair by
the NER pathway, or the cisplatin adduct could hinder the
DSB repair pathways by restricting the access of the protein
complexesinvolved.AnotherpossibilityisthattheNERandthe
DSB repair proteins may compete for access to the locally
multiply damaged site. Investigations into the efﬁciency of
NER have shown that NER is less efﬁcient if damaged sites
[cisplatin adducts and ultraviolet (UV) lesions] are near to a
DSB owing to binding of the DSB repair protein heterodimer
Ku70/80 at the DNA ends (4). In addition, decreased levels of
NER proteins bind to the lesion if a DSB is present (5,6).
The DSBs are repaired by the homologous recombination
(HR) pathway or the non-homologous end-joining (NHEJ)
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doi:10.1093/nar/gki528repair pathway, the latter being more error prone. The HR
pathway requires a DNA template strand, usually a sister
chromatid, whereas the NHEJ pathway has no such require-
ment [reviewed in (7–9)]. The basic NHEJ pathway [reviewed
in(7–10)]requiresanumberofproteins.Initially, theheterodi-
mer Ku70/Ku80 recognizes and binds to the free DNA ends at
a DSB in a sequence-independent manner. DNA-dependent
protein kinase catalytic subunit (DNA-PKcs) is then recruited
to the Ku heterodimer to form DNA-PK holoenzyme. The Ku
heterodimer can be translocated along the DNA strand as
the DNA passes through the hole in the Ku heterodimer
ring-like shape (11). The DNA-PK holoenzyme has kinase
activity, which recruits and co-ordinates repair proteins that
may be important in phosphorylating proteins in this pathway.
Finally, XRCC4 stimulates DNA ligase IV to join the broken
ends. Other components thought to be involved depending on
the type of DNA ends to be joined are inositol hexakis-
phosphate (12), Artemis (13), MRN complex (14) and DNA
polymerase m (15).
Previous work has shown that the presence of a cisplatin
adduct near a DSB may decrease the rate of Ku translocation
along the DNA strand and lowers the DNA-PK kinase activity
(16–18). However, these investigations were performed in the
presence of high levels of the puriﬁed components Ku70/80,
so that multiple Ku heterodimer molecules were shown to bind
and translocate along the DNA used. In addition, only the
initial steps of the NHEJ pathway were examined, so that
the ability to ligate two ends of DNA was not assessed.
These results have been conﬁrmed more recently (19) showing
that the cisplatin adducts do not alter the ability of Ku to bind
DNA ends, but do impair the translocation of Ku complex
along the DNA. Using a ligation assay with recombinant
Ku, XRCC4 and DNA ligase IV, the cisplatin adducts were
able to dramatically inhibit DNA ligation, whereas if no Ku
was present the high ligation levels were very slightly
decreased in the cisplatinated DNA. The ability to perform
ligation was dependent on the DNA substrate length. In the
present work, we examined the effect of cisplatin adduct
formation on the ability to perform NHEJ using cell-free
extracts,which contain the fullcomplementoffactorsrequired
for NHEJ, rather than recombinant proteins. We also used
large 3.2 kb DNA substrates rather than smaller DNA frag-
ments, which may limit the ability to form appropriate DNA
repair complexes around the DSB. DNA substrates with vary-
ing degrees of cisplatination were used ranging from sub-
strates where the entire DNA was cisplatinated, and hence
containing many different adduct types, to substrates with a
single intrastrand cis-[Pt(NH3)2fd(GpTpG)-N7(1),-N7(3)g]
[abbreviated as 1,3-d(GpTpG)] cisplatin adduct 10 bases
from the end of the DSB. We show that substrates containing
single, deﬁned terminal cisplatin adducts are more informative
than ‘globally’ cisplatinated substrates containing both
terminal and internal adducts in determining the effect of
cisplatin on NHEJ.
MATERIALS AND METHODS
Production of DNA substrates
Cisplatination of the linear 3.2 kb pGEM3zf+ plasmid
DNA (Promega, Southampton, UK) was carried out by the
incubation of 1 mgof the PstI restrictionenzyme cut DNA with
1.1–5.3 nmol of cisplatin (Sigma, Gillingham, UK) in 3 mM
NaCl, 0.5 mM Na2HPO4 and 0.5 mM NaH2PO4 at 37 C over-
night. Mock-treated DNA was incubated in buffer alone. The
reaction was stopped by the addition of 0.5 M NaCl, and the
DNA was puriﬁed using G25 spin columns (Amersham Phar-
macia, Buckinghamshire, UK). The sequence surrounding the
PstI site (shown in boldface) and the space with a underline
denotes the position of the restriction: 50-ACTATAGAA-
TACTCAAGCTTGCATGCCTGCA_GGTCGACACTAGT-
GGATCCAAAGAATTCAAAAAGCTTCT-30.
Cisplatination of plasmid DNA was also carried out on
the substrates shortcon and shortcis, which were constructed
by ligating into the EcoRI–HindIII site of pGEM3zf+




C_AATTGATATAAATCACA-30 dimerized with 50-AGC-
TTGTGATTTATATC_AATTGATAAATATCACAATG-30.
The region contains the MfeI restriction site (shown in bold-
face),whichwasusedtolinearizethesubstratesforend-joining
reactions,andthespacewithaunderlinedenotesthepositionof
the restriction. The shortcon and shortcis differ only in that a
GTG sequence is present in the shortcis substrate as shown in
italics. The longer substrates (longcon and longcis) contained
the following sequence ligated into the EcoRI–HindIII site of
pGEM3zf+. The longcon sequence was 50-AATTCAATA-
TAATTTTATAATATTATAATATTTATC_AATTGATAT-
AAATTATAATTTATAATTATTTATATTA-30 andthelong-
cis sequence was 50-AATTCAATATAATTTTATAATATT-
GTGATATTTATC_AATTGATATAAATCACAATTTATA-
ATTATTTATATTA-30. The longcon and longcis differ only
in that a GTG sequence is present in the longcis substrate as
shown in italics.
DNA substrates with one cisplatin adduct in the entire
molecule were produced using a 24 base oligonucleotide
containing the GTG site for cisplatination shown in boldface
(50-TCTTCTTCTGTGCACTCTTCTTCT-30). This 24mer
was puriﬁed by 15% denaturing PAGE (Sequagel, National
Diagnostics, Hessle, UK), identiﬁcation by staining with
SYBR Green I (Molecular Probes, Leiden, The Netherlands),
and isolated by electroelution (Elutrap, Schleicher and
Schuell, London, UK) followed by ethanol precipitation.
Cisplatination was carried out as described previously and
uncisplatinated and cisplatinated oligonucleotides were separ-
ated on a 15% denaturing polyacrylamide gel as described
previously (20). The cisplatinated and uncisplatinated DNA
were identiﬁed by UV shadowing and electroeluted. The con-
trol (con) or cisplatinated (cis) 24mer were annealed to either
oligonucleotide A (50-P-AATTAGAAGAAGAGTGCACA-
GAAGAAGACGCC-30)o rB( 5 0-P-AATTAGAAGAAGAG-
TGCACAGAAGAAGAGGCG-30) by heating equimolar
amounts of each oligonucleotide at 60 C for 5 min and leaving
to cool slowly over 2 h at room temperature. Oligonucleotides
A and B are identical in sequence apart from 4 nt shown above
in italics. Both oligonucleotides A and B were phosphorylated
at the 50 end and were designed such that annealing of either
with the 24mer (either con or cis) produced a double-stranded
molecule containing a 4 nt overhang at each end, with one
overhang beingcompatible with EcoRI digested plasmid DNA
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overhang being compatible between A and B. The resulting
annealed oligonucleotides, Acon, Bcon, Acis and Bcis,
were puriﬁed by separation in a 15% native gel followed
by electroelution and precipitation. Using T4 DNA ligase,
the annealed oligonucleotides were separately ligated to
pGEM3zf+ plasmid DNA linearized by EcoRI digestion.
Experiments were initially performed with different concen-
trations of annealed oligonucleotides and 50-fold molar excess
of oligonucleotides to plasmid DNA EcoRI ends was shown
to be sufﬁcient for >95% ligation. These four different ligated
substrates of DNA (Acon, Bcon, Acis and Bcis) were then
further puriﬁed by separation in a 0.6% agarose gel and puri-
ﬁcation using the QIAquick gel extraction kit (Qiagen Ltd,
Crawley,UK).Aninitialligationwas performed withT4 DNA
ligase in order to show that there was no recircularization,
and hence ligation of double-stranded oligonucleotides onto
the plasmid backbone had been successful. Analysis of the
32P-ATP end-labelled control and cisplatinated substrate by
restriction digest using ApaLI, or HindIII digestion followed
by exonuclease III action conﬁrmed the presence of the cis-
platin adduct on the manufactured DNA substrate (Figure 3B).
NHEJ assay
NHEJ extracts were produced essentially as described previ-
ously (21,22). End-joining reactions (20 ml) were carried out
with 40 mg protein extract from M059K cells and 20 ng DNA
substrate in the presence of 50 mM HEPES, pH 8.0, 40 mM
KOAc, 1 mM Mg(OAc)2, 1 mM ATP, 1 mM DTT, 0.1 mg/ml
BSA and 1 U RNase A at 37 C. For DNA substrates with one
cisplatin adduct in the entire molecule, equal amounts (10 ng)
of either cisplatinated (Acis and Bcis) or control (Acon and
Bcon) substrate were used. For example, 10 ng each of Acis
and Bcis substrates were mixed together to provide compatible
ends in the reaction mixture (in one reaction) to investigate the
effect of a cisplatin adduct on either side of a DSB, while in a
reaction with 10 ng each of Acis and Bcon substrates in the
reaction mixture the effect of a cisplatin adduct at only one
side of the DSB was examined. This was possible because
the A substratealone had incompatible 4ntoverhangs but with
the addition ofthe Bsubstrate, compatibleoverhangswould be
present in the reaction. Protein was removed by incubation
with proteinase K (2 mg/ml) and 0.5% (w/v) SDS for 30 min
and extraction with Tris-buffered phenol/chloroform/isoamyl
alcohol. Each assay was repeated at least three times. Reac-
tions were separated on 0.7% agarose gels, and signal quanti-
ﬁed by image analysis (Molecular Imager FX and the Quantity
One version 4.1.1 software; Bio-Rad Ltd, Hertfordshire, UK),
following SYBR Green I staining of the gel. To determine the
dependence of DNA joining on DNA-PK or Ku, Wortmannin
(10 mM; Sigma, UK) or anti-Ku70 antibody (1:20 dilution;
ab87, Abcam, UK), respectively, was included in the reaction
mixture in the absence of DNA for 10 min on ice before the
addition of DNA and incubation at 37 C.
RESULTS
NHEJ of cisplatinated plasmid DNA
The effect of cisplatin adducts on NHEJ was initially
examined usinga linear double-stranded 3.2 kb DNA substrate
with cohesive 30 four base overhangs produced by PstI diges-
tion where the entire DNA molecule had been exposed to
a range of cisplatin concentrations. Cisplatination reduced
levels of NHEJ by MO59K extract as measured by linear
dimer, trimer and higher multimer formation (Figure 1).
This effect was clearly dependent on the level of cisplatina-
tion achieved and no NHEJ was seen at the highest cisplatin
Figure 1. NHEJ of control and cisplatinated DNA substrate. End-joining
performed with MO59K extract and DNA substrate treated with cisplatin at
the following concentration (nmol) (A) 5.3, (B) 4.4, (C) 3.5, (D) 2.65, (E) 1.1
and (F) buffer only. NHEJ was measured over a time course where DNA was
incubated with extract for 0, 0.5, 1, 2, 3 and 4 h (lanes 1–6). The 3.2 kb linear
monomer (1·) was joined to form ligated linear dimers (2·), trimers (3·) and
higher multimers (m) as indicated. (G) Proportion of DNA substrate ligated
against time at the indicated cisplatin concentrations.
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PstI DNA ends showed a large number of potential sites
along the molecule where the cisplatin could form an adduct
(sequence in Materials and Methods). For example, both ends
of this substrate contained a GpG site, which if cisplatinated
could lead to fraying of the DNA ends (23), AG sites were
identiﬁed at 11 and 15 bp from the DNA ends, and potential
interstrand cross-links at 2/3, 6/7 and 10/11 bp on one side and
4/5 bp on the other side. Therefore, to distinguish the effect
of terminal cisplatin adducts from other cisplatin-mediated
effects on end-joining we constructed substrates with con-
trolled sites for cisplatination at the DNA ends. In a prelimin-
ary experiment we generated plasmid DNA cut with a second
restriction enzyme, Aﬂ III, which did not have any G bases at
the DNA ends, but did contain one GTG sequence adjacent to
the 30 cohesive overhang. Once again a decrease in NHEJ was
seen with increasing cisplatination (data not shown).
NHEJ of short AT-rich substrates
We reasoned that the introduction of one deﬁned GTG cisplat-
ination site at the termini of the substrate, which would be
surrounded by DNA containing a reduced number of potential
cisplatination sites, would allow us to determine the effect of a
terminal cisplatin adduct on NHEJ. We engineered two new
substrates (shortcon and shortcis) with fewer potential cisplat-
ination sites as no GG, AG or GNG sequences were present in
the immediate sequence surrounding the DSB owing to the
insertion of a 13 and 15 bp AT-rich DNA sequence on either
side of the DSB (sequence in Materials and Methods and
Figure 2A). Both substrates were linearized with MfeI and
the only difference between them was that the ‘shortcis’ sub-
strate had a GTG sequence inserted 10–12 bases from the
restriction site DSB restriction site. This GTG sequence
allowedtheproductionofa1,3-d(GpTpG)intrastrandcisplatin
adduct. This adduct was speciﬁcally selected to investigate
Figure 2. NHEJofshortandlongAT-richsubstrates.Sequenceoftheendsofthe(A)shortand(C)longAT-richcontrolandcisplatinatedDNAsubstrates.Double-
stranded oligonucleotides were ligated into pGEM plasmid DNA (underlined) with the MfeI restriction site shown in boldface. The inserted triangles show the
positionoftheGTGsequenceforcisplatination.Graphs(B)and(D)showthepercentageofligationproductsformedbyMO59KextractandDNAsubstratesshownin
(A) and (C), respectively. Substrates were either buffer treated or cisplatinated (2.65 nmol cisplatin). Experiments were performed in triplicate (–SD) and are
representative of three independent experiments.
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cisplatin-treated DNA, it is able to both bend and unwind the
DNA; therefore, causing substantial distortion of the DNA
helix [reviewed in (1)]. Once again, NHEJ by MO59K extract
wasmuchreducedwithincreasingcisplatinationconcentration
(data not shown). Comparison of the effect of cisplatination on
theshortcissubstraterevealedadecreaseinpercentageligation
products from 66 – 11% (–SEM) (buffer treated) to 18 – 5%
(cisplatinated) at 2 h. However, the same decrease was also
observed when the shortcon substrate (in which the terminal
GTG site was absent) was treated with cisplatin (70 – 10%,
buffer treated and 18 – 4%, cisplatinated) (Figure 2B). The
ligationobservedwithbothsubstrateswasDNA-PKcsdepend-
ent, as judged by Wortmannin sensitivity, and Ku-dependent,
using an anti-Ku antibody (data not shown).
NHEJ of long AT-rich substrates
The DNA substrates shortcon and shortcis had 13 and 15 bases
of the AT-rich sequence on either side of the DSB, which is
sufﬁcient for a single Ku heterodimer to bind to. But following
DNA-PKcs recruitment, the Ku heterodimer is predicted to
translocate away from the DSB and along the DNA by a
further 10 bases. This would mean that the translocated Ku
heterodimer would now also cover the original plasmid DNA
sequence which contained many potential cisplatination sites.
To minimize the possibility that cisplatin residues other than
the one 10 bases from the DSB site were inhibiting Ku trans-
location and hence NHEJ, two new substrates were engineered
with an extra 16 and 20 bases of AT-rich sequence on either
side (sequence in Materials and Methods and Figure 2C).
Similar to the effect seen with the short AT-rich substrates,
cisplatination of both control (longcon) and cisplatin-site
containing (longcis) substrates decreased ligation product
formation to the same extent. Percentage ligation for longcon
substrate was 69 – 10 (buffer treated) and 36 – 4% (cisplat-
inated),while for longcissubstrate was 63 – 11 (buffer treated)
and 31 – 2% (cisplatinated). However, we did note that both
the longer AT-rich substrates (longcon and longcis) were
signiﬁcantly less sensitive (P < 0.05) to the effects of cisplat-
ination than the short AT-rich substrate; percentage ligation
when cisplatinated was 36 – 4% (longcon), 31 – 2% (longcis),
18 – 4% (shortcon) and 18 – 5% (shortcis) at 2 h.
NHEJ of single 1,3-d(GpTpG) cisplatin
adduct substrates
In patients receiving concurrent chemoradiation, the doses of
cisplatin and radiation are such that we would not expect
clusters of cisplatin adducts in the DNA nor multiple cisplatin
adducts near each DSB (3). As it was possible that the addi-
tional monoadducts and the GA adduct within the AT-rich
region as well as global cisplatination inhibited NHEJ irre-
spective of the presence or absence of a single-terminal
cisplatin adduct, we investigated the joining of linear DNA
substrates containing one cisplatin adduct in the entire
molecule. DNA molecules (Acis and Bcis) were manufactured
wherebya1,3-d(GpTpG)cisplatinadductwaslocated10bases
from each DNA end. In parallel, control substrates (Acon and
Bcon) were made which were not cisplatinated. The 4 nt
overhangs of the DNA substrates were self-incompatible, so
that in reactions containing each substrate alone end-joining
could only occur between incompatible ends. However,
substrates A and B contained 4 nt 30 overhangs that were
compatible with each other such that, in the presence of
both substrates A and B, compatible end-joining could take
place (Figure 3A). Analysis using exonuclease III conﬁrmed
that the cis substrates contained the cisplatin adduct. Exonuc-
lease III acts upon 50 overhangs on double-stranded DNA, but
has no activity at 30 overhangs. Following HindIII digestion of
the DNA substrates, which creates a 50 overhang, exonuclease
III will digest the cisplatin adduct-containing strand starting
from the HindIIIsite andmovingtowards the engineered DSB.
The presence of a cisplatin adduct would impede the activity
of exonuclease III and would be predicted to result in a 12 bp
fragment (with a 4 base single-strand overhang) resistant
to digestion. An example of an exonuclease III digestion of
a DNA substrate is shown in Figure 3B. Here, the DNA con-
taining the cisplatin adduct is digested from the HindIII-
generated 50 overhang towards the 30 end of the molecule,
leaving a fragment of  13 base length (which migrated
more slowly owing to the cisplatin adduct), whereas the
non-cisplatinated control DNA produces smaller fragments
(Figure 3B).
NHEJ experiments were performed with combinations
of these substrates and showed that the DNA containing
1,3-d(GpTpG) cisplatin at both ends was less readily joined
than the non-cisplatinated control DNA, with ligation of 26%
(Acis plus Bcis) compared with 37% (Acon plus Bcon) of
substrate, respectively (Figure 4); a decrease in ligation efﬁ-
ciency of 30%. In total, four batches of both cisplatinated and
control substratemolecules wereindependently produced. The
actual levels of joining of the control substrates were lower
than those observed with the PstI cut substrate in Figure 1 and
the short and long AT-rich DNA substrates (35% ligated pro-
ducts compared with 70 and 55–60%, respectively). This may
reﬂect the multiple processing steps required to make the
substrate. In vivo it is more probable that a single cisplatin
adduct would occur on one side of a DSB rather than two
cisplatin adducts, one on either side of a DSB; experiments
were performed to mimic this situation using mixtures of
control and cisplatinated substrates with only one end of
the DNA containing a cisplatin adduct (i.e. Acon plus Bcis
or Bcon plus Acis) (Figure 4). Here, levels of NHEJ were
intermediate between the control DNA and the DNA sub-
strates cisplatinated at both ends. This joining was DNA-
PKcs dependent and Ku dependent (data not shown). We
also carried out experiments with the individual substrates
alone which have self-incompatible DNA ends. Again, the
majority of joining was both DNA-PKcs and Ku dependent
(Figure 4C). The NHEJ levels were lower than when comple-
mentary ends were present; this was as expected as incom-
patible end-joining is known to be a less-efﬁcient process
(24). Interestingly, the cisplatinated DNA with incompatible
ends was joined with lower efﬁciency than the corresponding
control DNA with incompatible ends (Figure 4A).
DISCUSSION
Using cell-free extracts, we have investigated the effects of
cisplatin adducts on the repair of DSBs by the NHEJ pathway.
This system is an advance in our understanding of this process
as no other study has used long (3.2 kb) DNA substrates with
Nucleic Acids Research, 2005, Vol. 33, No. 8 2535single cisplatin adducts or has used cell extracts that contain
all factors required for NHEJ and, more importantly, are at
the correct cellular concentration and relative molar ratios to
each other; hence, our system is more relevant to the in vivo
situation.
When treated with a high concentration of cisplatin, large
numbers of different adduct types were formed throughout the
entire substrate DNA, which led to a dramatic decrease in
NHEJ efﬁciency. As the cisplatin concentration was decreased
the adduct levels would decrease resulting in the reduction of
NHEJ inhibition. However, the actual adduct types and levels
formed were difﬁcult to control in the individual plasmid
molecules in these reactions. The reduction in end-joining
could be due to multiple effects of cisplatin including
the physical presence of cisplatin at or near the DNA ends
so inhibiting end processing and/or ligation of ends, or to the
distortion and denaturation of the DNA helix caused by the
cisplatin adducts present along the DNA. Another possibility
was that the recruitment of NER proteins to the cisplatin
adduct may hinder NHEJ. However, preliminary data using
the GM2246 cell line which is deﬁcient in XPC, a protein
known to be recruited early in the NER, suggested this last
possibility was not likely (data not shown).
Therefore, we designed further experiments to help discrim-
inate the effects ofterminalcisplatinadductsfromotherevents
associated with cisplatin treatment. We investigated the use of
substrates with different lengths of inserted AT-rich sequences
that did not contain the sequence GG or AG such that the most
common cisplatin adducts [the intrastrand 1,2-d(GpG) and
1,2-d(ApG) adducts] would not be formed in this region of
DNA near the DSB. We reasoned that these substrates could
be useful intermediates between using the ‘globally’ cisplat-
inated substrate (Figure 1), the effects of which are difﬁcult to
interpret, and the single adduct substrates (Figure 4), which are
more technically demanding and time-consuming to produce.
Although the longer AT-rich substrates were less sensitive to
the effect of cisplatin, surprisingly the presence of a single-
terminal GTG nucleotide sequence as a target site for cisplat-
ination had no signiﬁcant effect on the NHEJ efﬁciency. It is
possible that as these substrates contained purines and a GA
dinucleotide near the DSB, cisplatin monoadducts and 1,2
intrastrand adducts could be formed; however, it is more likely
that the distortion of the DNA structure by cisplatination at
multiple sites throughout the rest of the substrate was such that
the effect of a single GTG nucleotide sequence as a target site
for cisplatination could not be measured. Another possibility is
that the GTG sequence may not have been cisplatinated in all
substrate molecules owing to the large amount of other poten-
tial sites for global cisplatination. In addition, the actual length
of DNA over which the DNA-PKcs/Ku heterodimer complex
interacts, or that Ku translocates on recruitment of XRCC4/
ligase IV to the DNA ends (19) may be longer than the long
AT-rich regions by a further 20 bp, and so would extend into
the vector sequence that would contain multiple cisplatin
Figure 3. Manufacture of substrate with a single 1,3-d(GpTpG) cisplatin adduct. (A) Diagrammatic representation of substrate manufacture. (i) Oligonucleotides
were annealed to form double-stranded molecules with A plus 24mer (as shown here) or B plus 24mer. In each case the 24mer was cisplatinated (cis). The GTG
cisplatinationsiteisindicatedbyatriangleandEcoRIcompatibleoverhangshowninboldface.OligonucleotidesAandBwerephosphorylatedatthe50 end.(ii)These
double-stranded molecules were then ligated onto EcoRI linearized pGEM3zf+ plasmid DNA (indicated by horizontal lines and containing no other cisplatin
adducts).AcisandBcisareshownhere,AconandBconwereconstructedidenticallybutlackedthe1,3-d(GpTpG)cisplatinadductattheGTGcisplatinationsite.The
DNAsubstratesAcisandBcishadself-incompatibleendsbutwerecompatiblewitheachother.(iii)PositionofHindIIIsiteandpolarityofexonucleaseIIIdigestion.
The 12 base fragment resistant to digestion is indicated. (B) Exonuclease III analysis of substrates to confirm cisplatin adduct presence.
32P-end-labelled DNA
substrate was subject to restriction enzyme digestion with HindIII, subsequent exonuclease III digestion and denaturing acrylamide (15%) gel electrophoresis.
ControlBconsubstrate(lanes1and2),cisplatinatedBcissubstrate(lanes3and4),oligonucleotideBannealedtocontrol24mer(lane5),cisplatinatedoligonucleotide
B annealed to 24mer(lane6), 10 bp molecular weightmarker(lane 7).ExonucleaseIII digestionwasfor0 h (lanes1 and3) andfor 2h (lanes 2and 4–6). Thearrow
showsthepositionofthe12basefragments(whichmigratedat 13basesowingtothepresenceofthecisplatinadduct)remainingowingtotheblockageofnuclease
action by the cisplatin adduct.
2536 Nucleic Acids Research, 2005, Vol. 33, No. 8adducts. Therefore, multiple internal cisplatin adducts further
away from the termini, which could cause DNA distortion,
have a more profound effect on NHEJ such that we were not
able to measure the effect of terminal cisplatin adducts on
NHEJ using these intermediate substrates. Indeed, the longer
AT-rich constructs were less sensitive to the effects of global
cisplatination than the shorter constructs as the extra 16–20 bp
AT sequence inserted into the longer constructs, where there
was vector sequence before in the shorter constructs, again
reinforced the effect of multiple cisplatin adduct sites further
away from the actual DNA termini on NHEJ.
We then analysed the effect on NHEJ of a single adduct at
both ends of the DSB in a molecule with no other adducts
present, and the effect when only one DSB end had a cisplatin
adduct. The latter situation is more likely to occur in vivo.
NHEJ efﬁciency was reduced when both ends contained
cisplatin adducts by  30%, while a reduction of  20% was
found when a cisplatin adduct was present near only one
DNA end. It is not possible to directly compare the percentage
end-joining of substrates between experiments as substrates
with different terminal polarity and sequence were used.
Additionally, in experiments with substrates that had single
cisplatin adducts there was a mixture of compatible and
incompatible DNA ends, which were not phosphorylated.
End-joining efﬁciency can alter depending on the polarity
of DNA ends, the nucleotide sequence at the termini or the
nucleotide sequence internal to the DNA ends (21,25–27); we
have shown this in our work where termini differing by only
two bases were joined with different efﬁciencies (Acis com-
pared with Bcis; Figure 4B). This can be due to the differential
activation of DNA-PK. However, the results with global plat-
ination of substrate showed that, using the highest dose of
cisplatin, total NHEJ inhibition could be achieved (Figure 1)
wherethe adducts wouldbebothinternaland atthe DNA ends.
The multiple cisplatin adducts situated more internally in the
AT-rich substrates (Figure 2) also were able to substantially
reduce NHEJ at the cisplatin concentrations used, and at
higher levels of cisplatin could block NHEJ even more effect-
ively (data not shown). This indicated that multiple internal
adducts could have more inﬂuence on NHEJ than a single
terminal adduct, which caused a maximal 20–30% inhibition
(Figure 4). Similarly, it is likely that the multiple internal
adducts in the substrate used in Figure 1 could have more
inﬂuence on NHEJ than the single GG adduct site at the
extreme DNA end. This reinforces the importance of our
study using single deﬁned adducts and the difﬁculties inherent
in the interpretation of studies that use globally cisplatinated
substrates. These data argue against using globally cisplatin-
ated DNA substrates for determining the effect of terminal
cisplatin adducts on the NHEJ. While this work was under
review, studies by Pawelczak et al. (26) were published
that conﬁrmed the inhibitory effect on part of the NHEJ
pathway of cisplatin adducts close to the DSB. Using
puriﬁed DNA-PKcs and recombinant Ku they showed that
DNA-PK kinase activity, but not Ku binding, was signiﬁcantly
inhibited (95%) by the presence of a 1,2-d(GpG) intrastrand
cisplatin adduct 6 bp from the DNA terminus, while an adduct
15 bp away caused partial inhibition (60%). In view of the
different termini used and adduct types, it is not possible to
directly compare levels of inhibition with this work. The
authors propose a model whereby a cisplatin adduct close
to the terminus prevents the DNA substrate from fully thread-
ing through the kinase such that the single-stranded ends
would not be positioned in the activating cavity of DNA-
PKcssopreventingend-joining.Ourﬁndingsagreewithothers
in the ﬁeld who suggest that cisplatin adducts can decrease
NHEJ due to a decrease in the translocation rate of Ku and the
consequent decrease in DNA-PK kinase activity (16–19).
Figure 4. NHEJ efficiency in control and 1,3-d(GpTpG) cisplatinated DNA.
(A) Representative NHEJagarosegel ofDNA substrateseither uncisplatinated
(Acon + Bcon), 1,3-d(GpTpG)-cisplatinated at both ends (Acis + Bcis), 1,3-
d(GpTpG)-cisplatinated at one end (Acon + Bcis and Acis + Bcon) or single
substrates alone. Reactions were incubated for 2 h at 37 C. The 3.2 kb linear
monomer (1·) was joined to form ligated linear dimers (2·) and higher
multimers (m) as indicated. MW indicates 1 kb molecular weight markers.
(B) Correspondinggraphshowingthepercentage ligationformation.Theaver-
age of three independent experiments (–SEM) is shown. (C) End-joining
of self-incompatible DNA substrates in the presence (+) or absence ( )o f
Wortmannin (10 mM) or anti-Ku70 antibody (1:20 dilution). Linear monomer
(1·) and ligated linear dimers (2·) are indicated.
Nucleic Acids Research, 2005, Vol. 33, No. 8 2537However, assay systems distinct to ours were used by these
authorsincludingshorterlengthsofsubstrateDNA,sometimes
as low as 32 nt, and higher levels of Ku molecules. The rel-
evance of having multiple Ku complexes translocating along
the DNA strand in vivo is not known, as in vitro a single Ku
heterodimer is sufﬁcient to recruit DNA-PKcs (11), which
could indicate that in vivo a functional stoichometry is 1:1
for each DNA end. It is also unclear if DNA-PKcs is present in
one assay system (19). Our assay system not only provides a
measure of the entire Ku and DNA-PK dependent NHEJ pro-
cess in a more physiological setting but also allowed us to
study the effect of a single adduct, which is more relevant to
the situation in vivo (3).
In mammalian cells, ionizing radiation causes  40 DSBs
per cell per gray of radiation and, following cisplatin treat-
ment, one would expect 1–2 · 10
4 cisplatin adducts per cell
given a total of 3.3 · 10
9 bp per cell [based on the data and the
calculations from (3,28)]. In chemoradiation treatment, the
patient is pretreated with cisplatin before the radiotherapy
is administered so the assumption is made that cisplatin
adducts are present before the DSB are created. Therefore
after 2 Gy of radiation, Poisson statistics (3) predict there
to be a 0.5–1% probability of a cell having a single cisplatin
adduct within 10 bp of one end of a DSB, while the probability
of a cell having a cisplatin adduct at 10 bp from both ends of
the DNA involved in a DSB is inﬁnitesimally small. We have
shown that the presence of a cisplatin adduct at one end
reduces the NHEJ efﬁciency at 2 h by  20%. This equates
to approximately one in ﬁve end-joining events being delayed/
inhibitedby thepresence ofthe cisplatinadduct. Thereforeina
cell population treated with chemoradiation as described, we
would expect  0.1–0.2% (one-ﬁfth of 0.5–1%) to have DSB
rejoining delayed/inhibited by the presence of a cisplatin
adduct within 10 bp of one DSB end, a potentially deleterious
event as only one unrepaired DSB needs to remain within the
cell to initiate cell death. Repair of DSB induced by ionizing
radiation is efﬁcient, such that in vitro all but 10% of DSB are
repaired within 2 h of radiation (29), so any reduction in
efﬁciency of repair by the presence of a cisplatin adduct
could impact on treatment outcome.
The relative importance of NHEJ and HR in the repair of
DSB with a cisplatin adduct close by in vivo is not known. In
terms of cisplatin treatment alone, cisplatin exposure has no
effect on NHEJ-deﬁcient cells, whereas HR-deﬁcient cells are
more sensitive (30,31). This is due to the decrease/stalling of
replication fork progression by the presence of the cisplatin
adduct, which may lead to the production of DSBs [(32,33)
discussed in (34)]. This mechanism may be especially import-
ant in relation to the type of adduct formed as the most fre-
quent adduct, GpG, is refractory to repair by NER, while the
less-frequent GpNpG adduct is more efﬁciently repaired by
NER (35). In addition, interstrand cross-links formed by cis-
platin adducts require HR for their repair (36). Therefore,
although we have shown that NHEJ is impeded by the pres-
ence of a nearby cisplatin adduct, thus increasing radiosensit-
ivity, it is likely that a proportion of the radiosensitizing effect
ofcisplatinisrelatedtotheHRpathway.Wehave shownthata
single cisplatin adduct, either at one or both ends of the DNA
substrate, can decrease the joining of compatible DNA ends.
The MO59K cell line has previously been shown to join
incompatible DNA ends by NHEJ (24) and in this study we
have shownthat incompatible ends are joined less efﬁciently if
they contain a single cisplatin adduct. Our experiments with
exonuclease III indicate that exonuclease movement along the
DNA strand can be blocked by the presence of a single cis-
platin adduct, and it is known that the presence of adducts can
block DNA polymerases a, e and d (37,38), RNA polymerase
II and T7 RNA polymerase (39), although DNA polymerase b
can bypass adducts (38). This hinderance of nuclease and
polymerase action is likely to play a signiﬁcant role in the
inhibition of repair processes following concurrent chemora-
diation, where the ends of DSBs produced in response to
irradiation are unlikely to be compatible and may need to
be trimmed and ﬁlled-in prior to ligation.
In conclusion, using a cell-free extract system and an assay
for NHEJ we have shown that the presence of a single cisplatin
adduct near a DSB reduces NHEJ efﬁciency and that
this occurs at cellular cisplatin adduct levels commensurate
with clinical doses of concurrent chemoradiation. Therefore,
one mechanism by which cisplatin may exert its radiosensit-
izing effect is by reducing the efﬁciency of NHEJ. In addition,
this work demonstrates the limitations of the use of DNA
substrates containing any cisplatin adducts internal to the
DNA ends for determining the effect of cisplatinated substrate
termini on NHEJ.
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